However, an increase in tumor-associated CXCR2+ neutrophils compensated for the beneficial effects of CCR2+ macrophage-targeted therapy; therefore, targeting both myeloid cell types appears to be critical to improve response to chemotherapy.64 This evidence concerns the gene CCR2 and neoplasm.